Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-21
    E.g., 2018-11-21

Articles

19456 items
12:00 AM, Nov 08, 1993  |  BioCentury | Product Development

CYTL passes the baton in sepsis

CYTL passes the baton in sepsis Despite good safety data from a Phase I trial of its CY1787 monoclonal antibody for sepsis, Cytel Corp. has decided to give the product to its partner, sidestepping for...
12:00 AM, Nov 08, 1993  |  BioCentury | Strategy

SOMA and Baxter strike gene therapy deal

Precisely one year after a hoped-for strategic partnering deal fell through, Somatix Therapy Corp. has signed its first corporate deal, with Baxter Healthcare Corp., to develop a gene therapy approach for hemophilia. Under the agreement,...
12:00 AM, Nov 08, 1993  |  BioCentury | Strategy

CHMX blames poor Actinex sales on ignorance

Chemex Pharmaceuticals Inc., which reported disappointing Actinex sales, said the problem may be due to lack of patient awareness that there is a less-invasive treatment for actinic keratoses (premalignant skin lesions). CHMX had hoped...
12:00 AM, Nov 01, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Amgen Inc. (AMGN) Raymond James analyst Anthony Butler started coverage with a "buy," saying institutional investors have oversold the stock. Institutional holdings have fallen from 67.4 percent a year ago to 54.2 percent. He said...
12:00 AM, Nov 01, 1993  |  BioCentury | Strategy

Regulating return

Regulating return One of the fun and often instructive aspects of BioCentury's job involves finding connections between events. So it wasn't entirely surprising to uncover a link between this week's biotech meeting at the White...
12:00 AM, Nov 01, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Genzyme Corp. (GENZ) David Molowa of Bear, Stearns downgraded Genzyme Corp. to "hold" from "buy" due to lower earnings expectations in 1994 and beyond. While sales growth of currently marketed products is slowing and new...
12:00 AM, Nov 01, 1993  |  BioCentury | Politics, Policy & Law

White House meeting on biotech

WASHINGTON - A delegation of biotech leaders from San Diego, headed by Gensia Inc. Chairman, President & CEO David Hale, are scheduled to meet with health care advisor Ira Magaziner at the White House tomorrow...
12:00 AM, Nov 01, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Biogen Inc. (BGEN) Linda Miller of PaineWebber said the company's third quarter results were "handsomely above" her expectations, even though revenues from royalties and product sales were, as projected, lower than levels in the 1992...
12:00 AM, Nov 01, 1993  |  BioCentury | Regulation

Viral vectors get the green light

WASHINGTON - The FDA's Vaccines and Related Biological Products Advisory Committee gave a green light to the continued use of viral vectors for delivery of gene therapies and approved the FDA's current methods of regulating...
12:00 AM, Nov 01, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Alza Corp. Merrill Lynch analyst Richard Vietor raised his intermediate-term rating on Alza Corp. to "buy" from "above average," based on his belief that the log jam for new drug approvals, which has delayed AZA's12 pending...

Pages